Clinical Trial Update: Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating motesanib with or without carboplatin/paclitaxel or panitumumab in advanced non-small cell lung cancer, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Panitumumab (panitumumab)
• motesanib (motesanib)

Snippet

Sponsor: Amgen | Conditions: Lung Cancer, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-03-24